Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches

Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecul...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Aqsa Kanwal [verfasserIn] Farrukh Azeem [verfasserIn] Habibullah Nadeem [verfasserIn] Usman Ali Ashfaq [verfasserIn] Rana Muhammad Aadil [verfasserIn] A. K. M. Humayun Kober [verfasserIn] Muhammad Shahid Riaz Rajoka [verfasserIn] Ijaz Rasul [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	epithelial ovarian cancer anticarcinogenic network pharmacology active constituents gene ontology

Übergeordnetes Werk:	In: Pharmaceutics - MDPI AG, 2010, 14(2022), 9, p 1970
Übergeordnetes Werk:	volume:14 ; year:2022 ; number:9, p 1970

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/pharmaceutics14091970

Katalog-ID:	DOAJ005586127

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ005586127
003	DE-627
005	20240414192421.0
007	cr uuu---uuuuu
008	230225s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/pharmaceutics14091970 \|2 doi
035			\|a (DE-627)DOAJ005586127
035			\|a (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RS1-441
100	0		\|a Aqsa Kanwal \|e verfasserin \|4 aut
245	1	0	\|a Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC.
650		4	\|a epithelial ovarian cancer
650		4	\|a <i<Cassia fistula</i<
650		4	\|a anticarcinogenic
650		4	\|a network pharmacology
650		4	\|a active constituents
650		4	\|a gene ontology
653		0	\|a Pharmacy and materia medica
700	0		\|a Farrukh Azeem \|e verfasserin \|4 aut
700	0		\|a Habibullah Nadeem \|e verfasserin \|4 aut
700	0		\|a Usman Ali Ashfaq \|e verfasserin \|4 aut
700	0		\|a Rana Muhammad Aadil \|e verfasserin \|4 aut
700	0		\|a A. K. M. Humayun Kober \|e verfasserin \|4 aut
700	0		\|a Muhammad Shahid Riaz Rajoka \|e verfasserin \|4 aut
700	0		\|a Ijaz Rasul \|e verfasserin \|4 aut
773	0	8	\|i In \|t Pharmaceutics \|d MDPI AG, 2010 \|g 14(2022), 9, p 1970 \|w (DE-627)614096529 \|w (DE-600)2527217-2 \|x 19994923 \|7 nnns
773	1	8	\|g volume:14 \|g year:2022 \|g number:9, p 1970
856	4	0	\|u https://doi.org/10.3390/pharmaceutics14091970 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/1999-4923/14/9/1970 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1999-4923 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 14 \|j 2022 \|e 9, p 1970

Indexfelder

author_variant	a k ak f a fa h n hn u a a uaa r m a rma a k m h k akmhk m s r r msrr i r ir
matchkey_str	article:19994923:2022----::oeuamcaimoiasaitligiseihlaoainacrsnntokhrao
hierarchy_sort_str	2022
callnumber-subject-code	RS
publishDate	2022
allfields	10.3390/pharmaceutics14091970 doi (DE-627)DOAJ005586127 (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13 DE-627 ger DE-627 rakwb eng RS1-441 Aqsa Kanwal verfasserin aut Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC. epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology Pharmacy and materia medica Farrukh Azeem verfasserin aut Habibullah Nadeem verfasserin aut Usman Ali Ashfaq verfasserin aut Rana Muhammad Aadil verfasserin aut A. K. M. Humayun Kober verfasserin aut Muhammad Shahid Riaz Rajoka verfasserin aut Ijaz Rasul verfasserin aut In Pharmaceutics MDPI AG, 2010 14(2022), 9, p 1970 (DE-627)614096529 (DE-600)2527217-2 19994923 nnns volume:14 year:2022 number:9, p 1970 https://doi.org/10.3390/pharmaceutics14091970 kostenfrei https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 kostenfrei https://www.mdpi.com/1999-4923/14/9/1970 kostenfrei https://doaj.org/toc/1999-4923 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 9, p 1970
spelling	10.3390/pharmaceutics14091970 doi (DE-627)DOAJ005586127 (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13 DE-627 ger DE-627 rakwb eng RS1-441 Aqsa Kanwal verfasserin aut Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC. epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology Pharmacy and materia medica Farrukh Azeem verfasserin aut Habibullah Nadeem verfasserin aut Usman Ali Ashfaq verfasserin aut Rana Muhammad Aadil verfasserin aut A. K. M. Humayun Kober verfasserin aut Muhammad Shahid Riaz Rajoka verfasserin aut Ijaz Rasul verfasserin aut In Pharmaceutics MDPI AG, 2010 14(2022), 9, p 1970 (DE-627)614096529 (DE-600)2527217-2 19994923 nnns volume:14 year:2022 number:9, p 1970 https://doi.org/10.3390/pharmaceutics14091970 kostenfrei https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 kostenfrei https://www.mdpi.com/1999-4923/14/9/1970 kostenfrei https://doaj.org/toc/1999-4923 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 9, p 1970
allfields_unstemmed	10.3390/pharmaceutics14091970 doi (DE-627)DOAJ005586127 (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13 DE-627 ger DE-627 rakwb eng RS1-441 Aqsa Kanwal verfasserin aut Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC. epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology Pharmacy and materia medica Farrukh Azeem verfasserin aut Habibullah Nadeem verfasserin aut Usman Ali Ashfaq verfasserin aut Rana Muhammad Aadil verfasserin aut A. K. M. Humayun Kober verfasserin aut Muhammad Shahid Riaz Rajoka verfasserin aut Ijaz Rasul verfasserin aut In Pharmaceutics MDPI AG, 2010 14(2022), 9, p 1970 (DE-627)614096529 (DE-600)2527217-2 19994923 nnns volume:14 year:2022 number:9, p 1970 https://doi.org/10.3390/pharmaceutics14091970 kostenfrei https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 kostenfrei https://www.mdpi.com/1999-4923/14/9/1970 kostenfrei https://doaj.org/toc/1999-4923 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 9, p 1970
allfieldsGer	10.3390/pharmaceutics14091970 doi (DE-627)DOAJ005586127 (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13 DE-627 ger DE-627 rakwb eng RS1-441 Aqsa Kanwal verfasserin aut Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC. epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology Pharmacy and materia medica Farrukh Azeem verfasserin aut Habibullah Nadeem verfasserin aut Usman Ali Ashfaq verfasserin aut Rana Muhammad Aadil verfasserin aut A. K. M. Humayun Kober verfasserin aut Muhammad Shahid Riaz Rajoka verfasserin aut Ijaz Rasul verfasserin aut In Pharmaceutics MDPI AG, 2010 14(2022), 9, p 1970 (DE-627)614096529 (DE-600)2527217-2 19994923 nnns volume:14 year:2022 number:9, p 1970 https://doi.org/10.3390/pharmaceutics14091970 kostenfrei https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 kostenfrei https://www.mdpi.com/1999-4923/14/9/1970 kostenfrei https://doaj.org/toc/1999-4923 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 9, p 1970
allfieldsSound	10.3390/pharmaceutics14091970 doi (DE-627)DOAJ005586127 (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13 DE-627 ger DE-627 rakwb eng RS1-441 Aqsa Kanwal verfasserin aut Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC. epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology Pharmacy and materia medica Farrukh Azeem verfasserin aut Habibullah Nadeem verfasserin aut Usman Ali Ashfaq verfasserin aut Rana Muhammad Aadil verfasserin aut A. K. M. Humayun Kober verfasserin aut Muhammad Shahid Riaz Rajoka verfasserin aut Ijaz Rasul verfasserin aut In Pharmaceutics MDPI AG, 2010 14(2022), 9, p 1970 (DE-627)614096529 (DE-600)2527217-2 19994923 nnns volume:14 year:2022 number:9, p 1970 https://doi.org/10.3390/pharmaceutics14091970 kostenfrei https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 kostenfrei https://www.mdpi.com/1999-4923/14/9/1970 kostenfrei https://doaj.org/toc/1999-4923 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 9, p 1970
language	English
source	In Pharmaceutics 14(2022), 9, p 1970 volume:14 year:2022 number:9, p 1970
sourceStr	In Pharmaceutics 14(2022), 9, p 1970 volume:14 year:2022 number:9, p 1970
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology Pharmacy and materia medica
isfreeaccess_bool	true
container_title	Pharmaceutics
authorswithroles_txt_mv	Aqsa Kanwal @@aut@@ Farrukh Azeem @@aut@@ Habibullah Nadeem @@aut@@ Usman Ali Ashfaq @@aut@@ Rana Muhammad Aadil @@aut@@ A. K. M. Humayun Kober @@aut@@ Muhammad Shahid Riaz Rajoka @@aut@@ Ijaz Rasul @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	614096529
id	DOAJ005586127
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ005586127</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414192421.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/pharmaceutics14091970</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ005586127</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Aqsa Kanwal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">epithelial ovarian cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Cassia fistula</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticarcinogenic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">network pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">active constituents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gene ontology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farrukh Azeem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Habibullah Nadeem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Usman Ali Ashfaq</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rana Muhammad Aadil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. K. M. Humayun Kober</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Muhammad Shahid Riaz Rajoka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ijaz Rasul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmaceutics</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">14(2022), 9, p 1970</subfield><subfield code="w">(DE-627)614096529</subfield><subfield code="w">(DE-600)2527217-2</subfield><subfield code="x">19994923</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:9, p 1970</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/pharmaceutics14091970</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1999-4923/14/9/1970</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1999-4923</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2022</subfield><subfield code="e">9, p 1970</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Aqsa Kanwal
spellingShingle	Aqsa Kanwal misc RS1-441 misc epithelial ovarian cancer misc <i<Cassia fistula</i< misc anticarcinogenic misc network pharmacology misc active constituents misc gene ontology misc Pharmacy and materia medica Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
authorStr	Aqsa Kanwal
ppnlink_with_tag_str_mv	@@773@@(DE-627)614096529
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RS1-441
illustrated	Not Illustrated
issn	19994923
topic_title	RS1-441 Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches epithelial ovarian cancer <i<Cassia fistula</i< anticarcinogenic network pharmacology active constituents gene ontology
topic	misc RS1-441 misc epithelial ovarian cancer misc <i<Cassia fistula</i< misc anticarcinogenic misc network pharmacology misc active constituents misc gene ontology misc Pharmacy and materia medica
topic_unstemmed	misc RS1-441 misc epithelial ovarian cancer misc <i<Cassia fistula</i< misc anticarcinogenic misc network pharmacology misc active constituents misc gene ontology misc Pharmacy and materia medica
topic_browse	misc RS1-441 misc epithelial ovarian cancer misc <i<Cassia fistula</i< misc anticarcinogenic misc network pharmacology misc active constituents misc gene ontology misc Pharmacy and materia medica
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Pharmaceutics
hierarchy_parent_id	614096529
hierarchy_top_title	Pharmaceutics
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614096529 (DE-600)2527217-2
title	Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
ctrlnum	(DE-627)DOAJ005586127 (DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13
title_full	Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
author_sort	Aqsa Kanwal
journal	Pharmaceutics
journalStr	Pharmaceutics
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
author_browse	Aqsa Kanwal Farrukh Azeem Habibullah Nadeem Usman Ali Ashfaq Rana Muhammad Aadil A. K. M. Humayun Kober Muhammad Shahid Riaz Rajoka Ijaz Rasul
container_volume	14
class	RS1-441
format_se	Elektronische Aufsätze
author-letter	Aqsa Kanwal
doi_str_mv	10.3390/pharmaceutics14091970
author2-role	verfasserin
title_sort	molecular mechanisms of <i<cassia fistula</i< against epithelial ovarian cancer using network pharmacology and molecular docking approaches
callnumber	RS1-441
title_auth	Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
abstract	Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC.
abstractGer	Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC.
abstract_unstemmed	Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	9, p 1970
title_short	Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
url	https://doi.org/10.3390/pharmaceutics14091970 https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13 https://www.mdpi.com/1999-4923/14/9/1970 https://doaj.org/toc/1999-4923
remote_bool	true
author2	Farrukh Azeem Habibullah Nadeem Usman Ali Ashfaq Rana Muhammad Aadil A. K. M. Humayun Kober Muhammad Shahid Riaz Rajoka Ijaz Rasul
author2Str	Farrukh Azeem Habibullah Nadeem Usman Ali Ashfaq Rana Muhammad Aadil A. K. M. Humayun Kober Muhammad Shahid Riaz Rajoka Ijaz Rasul
ppnlink	614096529
callnumber-subject	RS - Pharmacy
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/pharmaceutics14091970
callnumber-a	RS1-441
up_date	2024-07-03T15:54:54.600Z
_version_	1803573887868338177
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ005586127</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414192421.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/pharmaceutics14091970</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ005586127</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1289eb6b2cad489ab966b57c80e8ef13</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Aqsa Kanwal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. <i<Cassia fistula</i< is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of <i<C. fistula</i< for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of <i<C. fistula</i< were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of <i<C. fistula</i< were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from <i<C. fistula</i< for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from <i<C. fistula</i<. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">epithelial ovarian cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Cassia fistula</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticarcinogenic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">network pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">active constituents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gene ontology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farrukh Azeem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Habibullah Nadeem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Usman Ali Ashfaq</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rana Muhammad Aadil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. K. M. Humayun Kober</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Muhammad Shahid Riaz Rajoka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ijaz Rasul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmaceutics</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">14(2022), 9, p 1970</subfield><subfield code="w">(DE-627)614096529</subfield><subfield code="w">(DE-600)2527217-2</subfield><subfield code="x">19994923</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:9, p 1970</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/pharmaceutics14091970</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1289eb6b2cad489ab966b57c80e8ef13</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1999-4923/14/9/1970</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1999-4923</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2022</subfield><subfield code="e">9, p 1970</subfield></datafield></record></collection>
score	7.401348

Nicht das Richtige dabei?

Schreiben Sie uns!

Molecular Mechanisms of <i<Cassia fistula</i< against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?